This study is in progress, not accepting new patients
Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
a study on Inflammatory Bowel Disease
Ulcerative Colitis Colitis Colitis, Ulcerative Ulcer Ozanimod RPC1063 RPC0163 (Ozanimod)
Lead Scientist at UCSF
- Jonathan Terdiman
Professor, Medicine. Authored (or co-authored) 111 research publications. Research interests: inflammatory bowel disease · Crohn's disease · ulcerative colitis · microbiome · colorectal cancer · Lynch syndrome · FAP.